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Objective: To investigate the effect of formulation parameters on the preparation of 
transfersomes as sustained-release delivery systems for lidocaine and to develop and validate a 
new HPLC method for analysis. 
Method: Taguchi design of experiment (DOE) was used to optimise lidocaine-loaded transfersomes 
in terms of phospholipid, edge activator (EA) and phospholipid:EA ratio. Transfersomes 
were characterised for size, polydispersity index (PDI), charge and entrapment efficiency (%EE). 
A HPLC method for lidocaine quantification was optimised and validated using a mobile phase of 
30%v/v PBS (0.01M):70%v/v Acetonitrile at a flow rate of 1ml/min, detected at 255nm with retention 
time of 2.84 minutes. The release of lidocaine from selected samples was assessed in-vitro. 
Key findings: Transfersomes were 200nm in size, with PDI∼0.3. HPLC method was valid for linearity 
(0.1-2mg/ml, R2 0.9999), accuracy, intermediate precision and repeatability according to ICH 
guidelines. The %EE was between 44-56% and dependent on the formulation parameters. Taguchi 
DOE showed the effect of factors were in the rank order: lipid: EA ratio ˃EA type ˃lipid type. 
Optimised transfersomes sustained the release of lidocaine over 24h. 
Conclusion: Sustained-release, lidocaine-loaded transfersomes were successfully formulated 
and optimised using a DOE approach and a new HPLC method for lidocaine analysis was developed 
and validated. 
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1. Introduction
Lipid-based vesicles such as liposomes, niosomes, transfersomes and proliposomes provide several 
advantages in comparison to polymeric and non-vesicular systems 1-5. A major advantage is their ability 
to deliver both hydrophilic and hydrophobic pharmacologically active drugs, and are mainly composed 
of biocompatible and biodegradable lipids that self-assemble in aqueous medium to form lipid bilayer 
membranes surrounding a hydrophilic core. Transfersomes were first introduced by Cevc et al. in 
which they added an edge activator (EA) or surfactant to the lipid components of liposomes 6. The 
elasticity induced by the presence of surfactant allows the resulting transfersomes to become more 
flexible than standard liposomes, enhancing their ability to pass through small pores and minimising 
the possibility of bilayer rupture that could occur with rigid liposomes 7, 8. Transfersomes have gained 
interest since they can be useful for both small molecular weight drugs and macromolecules, and may 
be delivered by many routes such as parenteral, transdermal or buccal 3, 9, 10.  
Local anaesthetics (LA) such as lidocaine, bupivacaine, and ropivacaine block the transmission of 
painful stimuli to the brain by acting on ion channels of nociceptor fibres, to achieve a control for both 
acute and chronic pain 11. In order to improve their pharmacokinetic properties, prolong their 
pharmacological activity and minimise their toxicity, many studies have formulated LAs in different 
forms such as injectable implants, films, microstructural systems, polymeric nanoparticles and lipid 
based vesicles 12, 13. However, most of the available LA forms have short duration of action, and 
frequent application are required to get long term pain relief which inversely affect the patient 
compliance and increase the side effects. A sustained release formulation of LA would be a great 
option to overcome the adverse effects of previously reported formulations. Having sustained release 
LA would reduce the need for multiple administrations regardless the route of administration 14, 15. 
Additionally, it would reduce the risks related to high dose applications. Moreover, sustained release 
LA formulation would help not only in producing anaesthesia for acute cases but would also aid the 
management of chronic pain. 
There are few licensed LA solution formulations to produce a prolonged effect allowing for a 
decreased frequency of injection. The prolonged effect is mainly gained by either the addition of a 
vasoconstrictor e.g. epinephrine, which prevents the leakage of the LA to the blood stream, or through 
liposomal and lipid-based Depofoam formulations 16, 17.  To our knowledge, several attempts have 
been made to formulate LAs as polymeric or lipid based microspheres and nanoparticles for injectable 
or transdermal drug delivery. However, most of the systems developed were not intended for 
sustained release administration. Hence, the aim of this work is to formulate sustained release LA- 
loaded transfersomes without the need to add vasoconstrictor or to use the complicated formulation 
method of Depofoam.    
Novel transfersomes loaded with LA such as lidocaine and intended to be a sustained release delivery 
system could be a better approach to improve patient compliance and achieve the required level of 
anaesthesia. However, the properties of drug loaded transfersomes usually vary with several 
parameters such as the nature of lipid and EA component, the concentration of each component, and 
the preparation process parameters 18. Although previous studies have attempted to find the optimum 
composition of transfersomes with some desired properties 19, 20, a new optimisation study was 
required since both the drug and sustained release transfersomes have not been reported in the 
literature to date. Optimisation of properties such as size and entrapment efficiency were essential in 
order to obtain transfersomes that could produce the required level of anaesthesia without any 
systemic side effects. Therefore, this study aimed to optimise the composition of transfersome with 
respect to parameters such as the type of lipids and the EA employed, using a Taguchi design of 
experiments (DOE) and lidocaine free-base was chosen as a model LA drug. 
Thus, the current study optimised the formulation parameters of a novel transfersome for sustained 
release of lidocaine by screening several types of lipid (natural and synthetic), several EAs (surfactants) 
with different HLB values, and several ratios of lipids to surfactants. Commonly, the more water-
soluble lidocaine hydrochloride salt is used for injectable forms, but the free-base is preferable since 
it exhibits more lipophilic properties. However, in order to use the free-base lidocaine a novel 
analytical method using high performance liquid chromatography (HPLC) was also developed and 
validated according to the International Council for Harmonisation (ICH) guidelines 21 as a reliable and 
more robust method for quantification of lidocaine in comparison with usual UV spectrometry 
method. 
2. Materials and methods 
 2.1 Materials 
 
Egg phosphatidylcholine (EPC), sodium deoxycholate (SDC), Tween 80, Span 80, and phosphate 
buffered saline (PBS, pH7.4) tablets were purchased from Sigma Aldrich, UK. Lidocaine (free-base), 
acetonitrile (ACN), methanol (MeOH), phosphotungstic acid and absolute ethanol were obtained from 
Fisher Scientific, UK. Di-Potassium hydrogen orthophosphate anhydrous was purchased from BDH 
Chemicals Ltd, UK. 1,2-Dimyristoyl-sn-glycero-3-phosphorylcholine (DMPC) was purchased from 
Lipoid, Switzerland. All solvents used were of HPLC grade. Whatman® polycarbonate filter membranes 
of 25mm diameter and 0.2μm pore size were purchased from Sigma Aldrich, UK. Spectra/Pro®3 





2.2.1 HPLC chromatographic system 
An HPLC system (1200 series) from Agilent Technologies, UK was used with diode-array detector (DAD) 
and Variable Wavelength Detector (VWD). An Agilent C18 column with dimensions of 4.6x150mm, 
and a particle size of 5μm was employed (Agilent Technologies, USA). The column oven temperature 
was set at 30 °C with an injection volume of 10µl. The final composition of the mobile phase was 
optimised with ACN and 0.01M phosphate buffer (70:30, v/v) at a flow rate of 1ml/min (the total run 
time was 5 minutes), and a UV detection wavelength of 255nm. 
2.2.2 Method development and validation 
To optimise the chromatographic conditions, the effect of several factors was analysed and 
investigated. These included mobile phase composition, flow rate, and detection wavelength (Table 
1). The optimised method was then validated according to ICH-guidelines 21. A stock solution of 
lidocaine and a set of diluted standard solutions were prepared. A calibration curve was plotted over 
the concentration range of 0.1 - 2mg/ml.  Linearity was evaluated according to the regression value 
(R2). Precision was confirmed by proving both repeatability and intermediate precision. Repeatability 
was assessed using a triplicate sample of 3 different lidocaine concentrations, while the intermediate 
precision was evaluated over 3 different days. The accuracy was measured by calculating the percent 
recovery and according to ICH by proving that the method is precise and linear. The Limit of Detection 
(LOD) and Limit of Quantification (LOQ) were assessed according to equations 1 and 2 respectively. 
Table 1. Parameters used in HPLC method development of lidocaine. 
 
𝐿𝑂𝐷 =  
3.3 × 𝑆𝐷
𝑆
                    (1) 
𝐿𝑂𝑄 =  
10 × 𝑆𝐷
𝑆
                    (2) 
Where SD is the standard deviation of the response, and S is the slope of the calibration line.  
2.2.3 Taguchi DOE 
Taguchi design was employed as a tool to optimise the transfersome formulation parameters. It was 
used to evaluate the effect of several formulation parameters such as the nature of lipid used (natural 
or synthetic), the type of surfactant (EA), and the ratio of lipid to surfactant (Table 2). The design was 
constructed using mixed level design (L18 array) with 3 factors, one factor has 2 levels and the other 
two factors has 3 levels (Table 2). Minitab® 18.1 software was used to construct the study design, and 
the selected response variables were investigated. The studied variables were transfersome size and 
entrapment efficiency (%EE). Table 3 summarises the composition of Taguchi design transfersome 
formulations. This design enables identifying and ranking the significant formulation factors that 
would have an effect on size and %EE.  
Table 2. Taguchi design of experiment including various factors and levels. 
 
Table 3. Summary of the composition of each formulation with different types of lipid (SPC, DMPC), EA (Span 
80, Tween 80 and SDC) and their ratios (95:5, 75:25 and 55:45 w/w) with each other. 
 
2.2.4 Preparation of transfersomes 
Lidocaine-loaded transfersomes were prepared using a lipid-based film hydration method 9, 19, 22 
(Figure 1). Transfersome formulations were prepared using compositions according to Taguchi DOE 
(Table 3). Lidocaine (70.29mg) was used in each formulation as the equivalent molar ratio to both 
phospholipid and EA ratio, and all components were dissolved in 12ml of absolute ethanol. The 
mixture was sonicated for 5 minutes to ensure complete dissolution of all components using a water 
bath sonicator (Model U500D, Ultrawave, UK). This was followed by the evaporation of ethanol using 
a rotary evaporator (Heidolph Laborota 4000 efficient, Germany) at 60˚C under reduced pressure. A 
continuous thin lipid film was obtained upon rotation (at 250 rpm) and after the complete evaporation 
of the ethanol. The lipid film was hydrated using 9ml of PBS (pH 7.4). The hydrated formulation was 
left to anneal for 30 minutes. Subsequently, formed transfersomes were extruded (Liposofast LF 50, 
Avestin, Germany), for 5 cycles at 45˚C using 200 nm membrane filters.  
 
Figure 1. Schematic diagram of transfersomes preparation method. 
 
2.2.5 Size, Polydispersity index (PDI), and Zeta potential 
Transfersomes were characterised for particle size, polydispersity index, and zeta potential using a 
dynamic light scattering (DLS) instrument (Zetasizer Nano; Malvern Instruments Ltd., UK). In this 
respect, 1ml of each formulation was transferred into the transparent Malvern zeta potential cuvette 
and placed in the instrument.  
2.2.6 Entrapment efficiency (%EE) 
The total drug concentration contained within each formulation was measured using a 0.5ml aliqout, 
which was diluted with methanol until a clear transparent solution was obtained. The drug 
concentration was then measured using the developed HPLC method (section 2.2.1). Another 0.5ml 
of the formulation was placed in a centrifugal filter tube of 3kDa pore size (Amicon® Ultra, Merck 
Millipore Ltd, Ireland) and centrifuged for 30 minutes with centrifugal force of 15.6 rcf  using benchtop 
centrifuge (Eppendorf Centrifuge 5415 D, Germany). The filtrate containing free drug at the bottom 
was diluted with methanol, and the concentration was measured via HPLC. The %EE was then 
calculated using equation 3.  
%𝐸𝐸 =  
(𝑡𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑐. −𝑢𝑛𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑐. )
𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑐.
 × 100                    (3) 
2.2.7 Transfersome morphology  
Transfersome morphology was observed under a transmission electron microscope (TEM) using a FEI 
Morgagni Transmission Electron Microscope (Philips Electron Optics BV, Netherlands). A drop of the 
transfersome suspension was placed on the copper grid and left for few minutes.  A drop of negative 
stain solution (phosphotungstic acid (1%)) was then added to the sample grid. The grid was then rinsed 
with distilled water to wash off the excess stain, and placed in the TEM sample chamber for 
visualisation.  
2.2.8 In-vitro release study 
The release profiles of selected samples based on DOE results were studied in vitro at 37˚C in addition 
to a control sample containing free lidocaine only. The release study was carried out in 500m vessels 
filled with 150ml PBS (pH7.4) on a magnetic stirrer at speed of 250rpm. Transfersome samples were 
sealed inside dialysis cellulose membrane with 3.5kD molecular exclusion pores, measuring 12cm, 
which were suspended in the PBS medium and incubated at 37˚C. Aliquots of 0.5ml of each sample 
were withdrawn at time intervals 0, 1, 3, 5, 7, 16 and 24 h. and replaced with a fresh PBS solution. The 
aliquots were then analysed using the developed HPLC method for the lidocaine content. 
2.2.9 Statistical analysis 
All data are presented as means with standard deviation (SD). A statistical analysis was performed on 
the data using one-way ANOVA with Tukey post-test or unpaired t-test analysis employing Minitab® 
18.1 software to determine any significant differences between the studied variables. The level of 
significance in difference was considered as p<0.05. 
3. Results and discussion  
3.1 HPLC method development 
Development of an HPLC method as an accurate method for the analysis of lidocaine free-base was 
necessary because the UV spectrophotometer was the most reported way to quantify the free-base, 
and all other reported HPLC methods were developed for the analysis of lidocaine HCl 23-27. Several 
methods suggested the use of ACN and PBS as mobile phase components for lidocaine analysis 23-26. 
To achieve good peak resolution, the use of a mobile phase with a basic pH has been suggested, while 
others have proposed the use of MeOH instead of ACN 27. Therefore, method optimisation and 
validation were required in order to improve lidocaine free-base analysis and investigation in 
formulations. The mobile phase composition, PBS molarity, detection wavelength and flow rate were 
adjusted to achieve high chromatographic resolution, and short retention time (Rt) of lidocaine free-
base. Twenty methods were designed to cover the variables and DAD was used to scan the absorbance 
over a range of wavelengths (Table 4). Upon applying these methods, it was found that some led to 
chromatograms showing poor peak shapes including broad peaks, fronting and tailing peaks (Table 4). 
Additionally, some methods resulted in a long Rt of lidocaine such as M7, M14 and M16 (11.30 min, 
14.30 min and 20.44 min, respectively). Further detection with methods employing slower flow rates 
(M8, M9, M15, M17, and M18) was not carried out, since a short run time was the aim of the method 
development. Among all methods, only three methods (M10, M11, and M12) gave a sharp peak with 
symmetry more than 0.90 and short retention time of lidocaine. However, M10 with 1.5ml/min flow 
rate was excluded as the drug peak occurred immediately after the solvent front. Method M11, 
employing a mobile phase of 30% PBS (0.01 M) and 70% ACN (%v/v), a flow rate 1 ml/min and a 
detection wavelength of 255 nm was chosen as it showed the highest peak resolution (Figure 2), and 
absorbance, as well as a reasonable test run time (5 minutes in total).  
Table 4. List of methods tested in the HPLC method development study including different mobile phase 





Figure 2. Representative lidocaine HPLC chromatogram obtained using method M11. 
3.2 HPLC method validation 
The validation parameters of the developed method are shown in Tables 5 and 6. The data showed 
good compliance with ICH guidelines 21. The analytical method revealed a linear relationship over the 
concentration range studied and the method was proven to be accurate and precise. 
Table 5. Validation parameters of lidocaine free-base. 
 
Table 6. Accuracy and precision (intermediate precision and repeatability). 
 
3.3 Transfersome preparation and characterisation  
3.3.1 Transfersome optimisation and Taguchi DOE analysis 
Taguchi design was used to determine the best formulation combination to achieve transfersomes 
with the minimum size and the highest %EE. The choice of design parameters was determined by 
previously reported studies. The type of phospholipids used has been investigated in several studies 
and has been reported to produce liposomal vesicles with different properties 28. Therefore, natural 
and synthetic phospholipids (EPC and DMPC) were investigated in this study. Additionally, it was 
reported that the surfactant type and concentration can also affect transfersome size and %EE 18. For 
this reason, three surfactants (EA) were used in this DOE in three different percentages (Table 2). 
Lidocaine-loaded transfersomes were prepared according to the designed experiments (Table 3). 
Transfersomes were then characterised as mentioned in the methods section for size, charge, 
morphology, and %EE (Table 7). 
Table 7. Transfersome formulation (F1-F18) characterisation results; size, polydispersity index (PDI), zeta 
potential, and entrapment efficiency (%EE). 
Transfersomes obtained by running the 18 experiments showed sizes below 208.70 ± 4.66 nm with 
consistent PDI, except two samples (F3 and F18), where transfersome sizes were unexpectedly large 
(515.35 ± 4.45nm and 671 ± 15.13nm respectively). Larger transfersomes may have been formed in 
these cases due to the high level of surfactant that was used, as it was previously reported that 
increased liposome size resulted from the presence of surfactant molecules situated within the lipid 
bilayer in a way that increased its diameter 29. Additionally, the %EE results obtained from all 18 
formulations ranged from 44.26 ± 2.61% (F 1) to 56.97 ± 0.18% (F 9). Statistical analysis of the obtained 
data was performed. The %EE results of all 18 formulations showed no significant differences (P> 
0.05). The low encapsulation efficiency was suggested to be related to the size of transfersome. As 
the drug has lipophilic properties it should be entrapped within the lipid bilayer, however, the small 
size does not offer enough space within the bilayer for large amount of drug to accommodate. Higher 
entrapment would be expected with micron-sized transfersomes 19, however, nanosized 
transfersomes are preferable for any route of delivery, including buccal 30, 31, transdermal 32, 33 and 
parenteral 34. It is claimed that both the nanosize and the deformability of transfersomes are the key 
characteristics for enhanced tissue permeation when administered topically (transdermal or buccal), 
in addition to the improved solubility, targeting and stability when injected intravenously 32, 34, 35.  
In contrast, statistical analysis of transfersome size showed a considerable variation (Figure 3). There 
was a significant difference in size between most samples that included 5% and 25% EA in comparison 
to 45%, with P values of either *P< 0.05 or ***P<0.001 (Figure 3 A, B C, E and F). A small but significant 
difference (with P<0.05) was also noted between samples that included EA of 5% in comparison to 
samples that had 25% EA (Figure 3 A, B, E, and F).  
The results were analysed using Taguchi analysis in Minitab® 18 software, in which the variation of the 
response was studied using signal to noise (S/N) ratio. S/N ratio is a quality analytical parameter which 
is useful to determine the best level of each experimental parameter. The type of S/N ratio is 
selected depending on the desired characteristic. A larger S/N ratio was considered desirable for the 
analysis of the %EE results, as a high level of drug entrapment is desirable. However, because 
there was not a significant difference between the %EE results of the 18 formulations, the Taguchi 
analysis was carried out considering only transfersome size. In this case, a small S/N ratio was 
considered desirable for the analysis, as smaller transfersome size is preferable (Table 8). The 
analysis enabled ranking the studied parameters in accordance with the magnitude of their effect on 
the size of transfersomes. Both the type of surfactant and its concentration were clearly 
observed to be the most significant factors affecting transfersome sizes (Table 8). Additionally, 
samples that were prepared with Tween 80 showed the smallest size, followed by SDC and Span 
80 (Figure 4). Furthermore, it was also found that the employed concentration of the EA has a 
noticeable effect on transfersome size, since increasing the concentration from 5% to 25% clearly 
resulted in a size reduction. However, further increment of surfactant concentration up to 45% 
showed a contrasting effect (Figure 4). Transfersome sizes were increased in formulations with a 
high surfactant concentration as a result of the molecular repulsion that possibly occurred 
between the surfactant and phospholipid molecules within transfersome bilayers 18, 29. 
Additionally, the analysis also showed that the use of either natural or synthetic 
phospholipids had no significant effect on the size of transfersomes and their ability to entrap drug.  
Figure 3. Graphical representation of transfersomes size of all 18 formulations. 
Table 8. Response table for Signal to Noise ratios (S/N), showing the rank of the factors X1, X2 and X3 as they 
affect transfersome size. 
Figure 4. Effect of studied parameters using the mean of S/N ratios. 
3.3.2 Zeta potential 
Measuring zeta potential of the obtained transfersomes was crucial to determine since it was claimed 
that it could affect the permeation rate when they administered transdermally or through the buccal 
tissue 20. For example it was reported that transfersome with high negative charge will effectively 
enhance their skin permeation 7.  The results revealed that all prepared transfersomes hold a negative 
charge (Table 7). This can be explained as the net surface charge of the transfersomes depends mainly 
on both phospholipid and surfactant character. Both EPC and DMPC are zwitterionic compounds with 
an isoelectric point of 6-7, meaning that at the current experimental conditions (pH = 7.4) they hold a 
net negative charge 20, 36. Moreover, samples that were prepared using SDC (F7, F8, F9, F16, F17, and 
F18) were observed to carry a higher negative charge than Tween 80 and Span 80 based samples. 
Additionally, the negative charge increased dramatically from -6.86 mV up to -21.70 mV as the SDC 
concentration increased from 5% (formulation F7) to 45% (F9). Similarly, it increased from -3.60mV to 
-18.65 mV in formulations F16 to F18, which was in good agreement with the literature since the 
surfactant concentration affects the final charge of the lipid vesicles 20, 37.
3.3.3 Transfersome morphology 
The morphology of lidocaine loaded transfersomes was observed using TEM (Figure 5). Transfersomes 
displayed a uniform, spherical shape with intact bilayer membrane, and unilamellar bilayer structure. 
TEM images confirmed that transfersomes were effectively achieved and they were found to be 
approximately 200nm in size. 
Figure 5. TEM images of transfersomes produced by F4. 
3.3.4 In-vitro release 
According to the optimisation study results, 6 samples were selected for the in vitro-release study. As 
the Lipid: EA ratio had the major effect on the transfersomes properties, the samples were chosen 
from the ratio that gave the desired properties, which was 75:25 of lipid: EA (Table 8). Although the 
lipid type did not show a significant effect (p>0.05) from the optimisation results, the selected 
six samples were prepared using both lipids; EPC (F2, F5, and F8) and DMPC (F11, F14, and F17) in 
order to check their effect on the release profile. However, as the EA type was the second important 
factor to produce the desired transfersomes all 3 EA were considered in the selection of samples 
(Table 7). The release profile of the 6 samples in addition to a control of free drug was studied over 
24 hours. The cumulative amount of drug released was calculated for each formulation (Table 9). 
The release profile of the control sample (free drug) revealed that 96% drug amount passed across 
the dialysis membrane by 1 hour, while all 6 transfersome samples showed complete drug release 
at 24h (Table 9, Figure 6). Transfersomes samples that were prepared by EPC not only showed 
sustained release of lidocaine but also a delayed release, with < 2% drug released after 1h 
(F2, F5, and F8), but subsequently almost 60% after 3h (Table 9). DMPC-based transfersomes 
showed between 5-21% drug release after 1h. The release profiles of the six formulations 
proved that transfersomes were successfully optimised and prepared to sustain the release 
lidocaine over 24h. Moreover, it is a 
promising system to deliver LA via any route with a reduced frequency of administration, which in 
turn would reduce side effects and enhance the pain management (both acute and chronic) 15, 17.   
Table 9. In-vitro release study results, % drug released over several time points, n=3 ± SD 
Figure 6. Release profile of lidocaine permeated across dialysis bag from 6 different transfersomes formulations 
versus the free drug (control) over 24h. 
Conclusion 
In this study, transfersomes were optimised to develop sustained release delivery system of lidocaine. 
They were formulated using a simple lipid film hydration method. Preparation parameters were 
optimised using a Taguchi DOE in terms of phospholipid type, type of EA and ratio of phospholipid to 
EA. Transfersomes were characterised for size, PDI, charge, and %EE. The obtained transfersomes 
were approximately 200 nm in size with PDI ≤ 0.3. To determine the entrapment efficiency, a new 
HPLC method for lidocaine was optimised and validated according to ICH guidelines. The proposed 
method was validated for linearity, accuracy, sensitivity, intermediate precision and repeatability, and 
was shown to be valid to for the analysis of lidocaine free-base according to ICH guidelines. The 
calculated %EE varied as the formulation parameters changed, but was generally between 44-56%. 
Analysing the data obtained by Taguchi DOE showed that the effect of formulation factors on both 
size and %EE were in the following rank order: lipid: EA ratio ˃EA type ˃lipid type. The type of lipid 
(natural or synthetic) showed no significant effect on transfersome size. Increasing the EA 
concentration up to 25% resulted in a reduction in transfersomes size; however, with a further 
increase in EA, transfersome size was seen to increase.  
Transfersome samples were selected based on the analysis of the optimisation results, and their 
release profiles were assessed. All 6 samples proved that the optimised transfersomes can be used as 
a sustained release delivery system of LA as they released lidocaine slowly over 24h in contrast to the 
free drug that showed complete drug release by 1 hour. 
These samples will be employed in future work for testing their ex-vivo release and permeability 
profile.  
Table 7. Parameters used in HPLC method development of lidocaine. 
Parameters Value  
Mobile phase solution - 0.01M Phosphate buffer: Acetonitrile (70:30, 50:50, 30:70) 
- Water: Methanol (30:70,50:50, 70:30) 
- 0.1M Phosphate buffer: Acetonitrile  (30:70) 
Detection wavelength 220 - 290 nm  
 




Table 8. Taguchi design of experiment including various factors and levels. 
Factors (X) 
Level 
1 2 3 
Lipid type (X1) EPC  (natural lipid) DMPC (synthetic lipid) - 
EA (HLB) (X2) Span 80 (4.3) Tween 80 (15) SDC (16) 






Table 9. Summary of the composition of each formulation with different types of lipid (SPC, DMPC), EA (Span 
80, Tween 80 and SDC) and their ratios (95:5, 75:25 and 55:45 w/w) with each other. 






F1 EPC Span 80 95:5 
F2 EPC Span 80 75:25 
F3 EPC Span 80 55:45 
F4 EPC Tween 80 95:5 
F5 EPC Tween 80 75:5 
F6 EPC Tween 80 55:45 
F7 EPC SDC 95:5 
F8 EPC SDC 75:5 
F9 EPC SDC 55:45 
F10 DMPC Span 80 95:5 
F11 DMPC Span 80 75:5 
F12 DMPC Span 80 55:45 
F13 DMPC Tween 80 95:5 
F14 DMPC Tween 80 75:5 
F15 DMPC Tween 80 55:45 
F16 DMPC SDC 95:5 
F17 DMPC SDC 75:5 
F18 DMPC SDC 55:45 
Table 10. List of methods tested in the HPLC method development study including different mobile phase 
composition, flow rate and detection wavelengths, with the obtained results including their Rt, symmetry, and 
shape. 
Method 









M1 Water: MeOH (30:70) 1.5 4.83 0.71 broad and tailing peak  
M2 Water: MeOH (30:70) 1 7.23 0.60 broad and tailing peak 
M3 Water: MeOH (30:70) 0.5 8.08 0.67 sharp peak 
M4 Water: MeOH (50:50) 1.5 8.60 0.43 broad and tailing peak 
M5 Water: MeOH (50:50) 1 5.38 0.44 broad and tailing peak 
M6 Water: MeOH (50:50) 0.5 3.08 0.58 fronting peak 
M7 Water: MeOH (70:30) 1.5 11.30 0.44 broad and tailing peak 
M8 Water: MeOH (70:30) 1 - - - 
M9 Water: MeOH (70:30) 0.5 - - - 
M10 PBS (0.01M): ACN (30:70) 1.5 1.59 0.90 sharp peak 
M11 PBS (0.01M): ACN (30:70) 1 2.84 0.93 sharp peak 
M12 PBS (0.01M): ACN (30:70) 0.5 4.46 0.95 sharp peak  
M13 PBS (0.01M): ACN (50:50) 1.5 3.66 0.71 fronting peak 
M14 PBS (0.01M): ACN (50:50) 1 14.30 0.73 fronting peak 
M15 PBS (0.01M): ACN (50:50) 0.5 - - - 
M16 PBS (0.01M): ACN (70:30) 1.5 20.44 0.58 tailing peak 
M17 PBS (0.01M): ACN (70:30) 1 -  - 
M18 PBS (0.01M): ACN (70:30) 0.5 -  - 
M19 PBS (0.1M): ACN (30:70) 1.5 1.59 0.91 fronting peak 
M20 PBS (0.1M): ACN (30:70) 1 2.49 0.79 fronting peak 
 
 








(y= ax ± b) y= 1106.2x-0.1751 
R2 0.9999 
Linearity range 0.1-2 mg/ml 
LOD  1.55x10-07 mg/ml 
LOQ 4.72x10-07 mg/ml 




Day 1 Day 2 Day 3 
Accuracy (%) RSD (%) Accuracy (%) RSD (%) Accuracy (%) RSD (%) 
0.2 100.43 0.08 97.60 0.06 97.70 0.09 
0.4 99.56 0.05 97.95 0.01 96.93 0.09 




Table 7. Transfersome formulation (F1-F18) characterisation results; size, polydispersity index (PDI), zeta 
potential, and entrapment efficiency (%EE). 




F1 188.60 ± 9.33 0.18 ± 0.02 -4.66 ± 1.42 44.26 ± 2.61 
F2 208.70 ± 4.66 0.25 ± 0.03 -4.56 ± 0.29 51.73 ± 1.51 
F3 515.35 ± 4.45 0.29 ± 0.12 -7.49 ±0.84 53.87 ± 5.73 
F4 181.05 ± 11.66 0.18 ± 0.03 -3.14 ± 0.21 45.82 ± 3.98 
F5 146.95 ± 0.63 0.22 ± 0.02 -2.15 ± 1.20 49.83 ± 2.07 
F6 121.15 ± 1.34 0.22 ± 0.04 -2.77 ± 0.05 50.19 ± 2.02 
F7 195.95 ± 7.28 0.14 ± 0.00 -6.86 ± 1.16 53.05 ± 0.62 
F8 98.93 ± 2.07 0.14 ± 0.01 -17.10 ± 0.28 54.55 ± 1.05 
F9 134.85 ± 12.51 0.26 ± 0.03 -21.70 ± 0.28 56.97 ± 0.18 
F10 188.00 ± 22.06 0.13 ± 0.00 -1.28± 1.33 50.76 ± 0.72 
F11 200.35 ± 19.02 0.21 ± 0.01 -3.25 ± 0.34 48.93 ± 4.12 
F12 194.30 ± 15.41 0.15 ± 0.00 -4.65 ± 0.03 53.07 ± 4.44 
F13 171.15 ± 3.18 0.19 ± 0.00 -0.48 ± 0.76 52.96 ± 4.44 
F14 96.92 ± 16.37 0.17 ± 0.01 -1.15 ± 1.17 50.67 ± 0.21 
F15 116.00 ± 6.64 0.19 ± 0.01 3.94 ± 2.12 50.80 ± 1.22 
F16 153.70 ± 28.28 0.15 ± 0.01 -3.60 ± 0.57 50.93 ± 2.07 
F17 146.05 ± 0.35 0.30 ± 0.02 -13.20 ± 1.27 52.63 ± 0.12 
F18 671.00 ± 15.13 0.59 ± 0.16 -18.65 ± 1.62 55.72 ± 7.33 
 
  
Table 8. Response table for Signal to Noise ratios (S/N), showing the rank of the factors X1, X2 and X3 as they 
affect transfersome size. 
Level X1 X2 X3 
1 -45.03 -47.24 -45.07 




Delta 0.49 4.50 4.52 




Table 9. In-vitro release study results, % drug released over several time points, n=3 ± SD 
Time 
points  



































































































Figure 4. Representative lidocaine HPLC chromatogram obtained using method M11. 
 













Figure 5. TEM images of transfersomes produced by F4.  
 
Figure 6. Release profile of lidocaine permeated across dialysis bag from 6 different transfersomes formulations 
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